Showing 18,261 - 18,280 results of 18,355 for search '(( 50 ((((ng decrease) OR (we decrease))) OR (a decrease)) ) OR ( 5 cm decrease ))', query time: 0.62s Refine Results
  1. 18261

    Table_11_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  2. 18262

    Table_15_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  3. 18263

    Loss of MLL1 in adult mice. by Neha Goveas (11790822)

    Published 2021
    “…<p>(A) Giemsa-stained sections from the femur of <i>Mll1</i><sup><i>FC/+; RC/+</i></sup> and <i>Mll1</i><sup><i>FC/FC; RC/+</i></sup> mice. …”
  4. 18264

    Table_5_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  5. 18265

    Data_Sheet_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.PDF by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  6. 18266

    Table_9_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  7. 18267

    Table_4_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  8. 18268

    Image 3_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff by Peiqin Shi (22130170)

    Published 2025
    “…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”
  9. 18269

    Image 2_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff by Peiqin Shi (22130170)

    Published 2025
    “…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”
  10. 18270

    Image 1_CS Ratio is an immune-related prognostic biomarker for cervical cancer.tiff by Peiqin Shi (22130170)

    Published 2025
    “…The CS polarization state reflects a highly coordinated network of pro-tumor anti-tumor variables offering a simplified yet effective immune response indicator for the complex TME. …”
  11. 18271

    S1 Data - by Renjie Wang (1986553)

    Published 2025
    “…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
  12. 18272

    S3 Data - by Renjie Wang (1986553)

    Published 2025
    “…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
  13. 18273

    S2 Data - by Renjie Wang (1986553)

    Published 2025
    “…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
  14. 18274

    S5 Data - by Renjie Wang (1986553)

    Published 2025
    “…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
  15. 18275

    S6 Data - by Renjie Wang (1986553)

    Published 2025
    “…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
  16. 18276

    S4 Data - by Renjie Wang (1986553)

    Published 2025
    “…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
  17. 18277

    S7 Data - by Renjie Wang (1986553)

    Published 2025
    “…Notably, moderate (D2) and severe (D3) drought treatments led to negative GD values. GD decreased by 23.79%, 114.85%, and 175.50% for D1, D2, and D3 treatments, respectively, while reductions of 40.00%, 73.33%, and 90.00% in GD were observed compared to the control (CK). …”
  18. 18278

    Factors affecting LLINs usage at household level. by Job Oyweri (22041452)

    Published 2025
    “…Not owning a bed decreased the likelihood of net usage by 13.3% [aOR=0.867 (95% CI = 0.816–0.920), p < 0.001]. …”
  19. 18279

    Net usage across intervention arms. by Job Oyweri (22041452)

    Published 2025
    “…Not owning a bed decreased the likelihood of net usage by 13.3% [aOR=0.867 (95% CI = 0.816–0.920), p < 0.001]. …”
  20. 18280

    Factors associated with malaria infection. by Job Oyweri (22041452)

    Published 2025
    “…Not owning a bed decreased the likelihood of net usage by 13.3% [aOR=0.867 (95% CI = 0.816–0.920), p < 0.001]. …”